

XOMA Corp (XOMA) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/X048CE257FCEEN.html>

Date: April 2020

Pages: 50

Price: US\$ 125.00 (Single User License)

ID: X048CE257FCEEN

Abstracts

XOMA Corp (XOMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

XOMA Corp (Xoma), formerly Xoma Ltd, is a biopharmaceutical company. It develops antibody-based therapeutics. Its lead product, Gevokizumab is a monoclonal antibody used for the treatment of a wide variety of inflammatory diseases and other diseases. Its other pipeline products include RZ358, XMetA, X213 (formerly LFA 102) and PTH1R. XOMA X358 is a human negative allosteric modulating insulin receptor antibody; X213 is an allosteric inhibitor of prolactin action. Xoma has a developed proprietary antibody platform, optimization and development technologies, comprising ADAPT, ModulX and OptimX. It operates through its subsidiaries in Bermuda, Ireland and the US. Xoma is headquartered in Berkeley, California, the US.

XOMA Corp Key Recent Developments

Mar 10,2020 XOMA reports fourth quarter and full-year 2019 financial results and operating highlights

Nov 05,2019 XOMA reports third quarter 2019 Royalty asset portfolio highlights and financial results

Aug 12,2019 XOMA's royalty portfolio expands significantly

Aug 06,2019 XOMA reports second quarter 2019 Royalty Asset portfolio highlights and financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

XOMA Corp - Key Facts
XOMA Corp - Key Employees
XOMA Corp - Key Employee Biographies
XOMA Corp - Major Products and Services
XOMA Corp - History
XOMA Corp - Company Statement
XOMA Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
XOMA Corp - Business Description
Geographical Segment: Asia Pacific
Performance
Geographical Segment: Europe
Performance
Geographical Segment: United States
Performance
XOMA Corp - Corporate Strategy
XOMA Corp - SWOT Analysis
SWOT Analysis - Overview
XOMA Corp - Strengths
XOMA Corp - Weaknesses
XOMA Corp - Opportunities
XOMA Corp - Threats
XOMA Corp - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance

Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
XOMA Corp, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Mar 10, 2020: XOMA reports fourth quarter and full-year 2019 financial results and operating highlights

Nov 05, 2019: XOMA reports third quarter 2019 Royalty asset portfolio highlights and financial results

Aug 12, 2019: XOMA’s royalty portfolio expands significantly

Aug 06, 2019: XOMA reports second quarter 2019 Royalty Asset portfolio highlights and financial results

May 06, 2019: XOMA reports first quarter 2019 financial results and operating highlights

Mar 07, 2019: XOMA reports fourth quarter and full year 2018 financial results and operating highlights

Jan 03, 2019: Xoma names Barbara Kosacz as board director

SECTION 5 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

XOMA Corp, Key Facts
XOMA Corp, Key Employees
XOMA Corp, Key Employee Biographies
XOMA Corp, Major Products and Services
XOMA Corp, History
XOMA Corp, Subsidiaries
XOMA Corp, Key Competitors
XOMA Corp, Ratios based on current share price
XOMA Corp, Annual Ratios
XOMA Corp, Annual Ratios (Cont...1)
XOMA Corp, Interim Ratios
XOMA Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

XOMA Corp, Performance Chart (2015 - 2019)
XOMA Corp, Ratio Charts

COMPANIES MENTIONED

Osiris Therapeutics Inc
Emergent BioSolutions Inc
Lux Biosciences Inc
Soligenix Inc
EyePoint Pharmaceuticals Inc

I would like to order

Product name: XOMA Corp (XOMA) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/X048CE257FCEEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/X048CE257FCEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970